Molecules, Vol. 25, Pages 1725: A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma
Conclusion: Local delivery of iRed could augment the in vivo gene silencing effect without eliciting pronounced innate immune stimulation. Our results might hold promise for widespread utilization of iRed as an RNAi-based therapeutic for intracelial malignant cancers.
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Feature Editor's Introduction —Malignant pleural mesothelioma (MPM) is a highly fatal cancer of the pleura that has been defeating standard and investigational therapies since its first description. The efficacies of chemotherapy, radiotherapy, and surgical therapy are limited, and we have been writing for decades that improve d therapies are needed. MPM is born of inflammation, and approximately 80% of cases are associated with the smoldering tissue inflammatory responses against the carcinogenic fibers of asbestos.
ConclusionsThere was not enough data to evaluate the efficacy because the study was terminated early. However, amrubicin showed limited activity andacceptable toxicities when used in previously treated malignant pleural mesothelioma patients.
Surgical oncologist and mesothelioma specialist Dr. Byrne Lee spent close to a decade in Southern California, building a well-respected peritoneal surface malignancy program at City of Hope Comprehensive Cancer Center. He wants to build a bigger and better one now — second to none — almost 400 miles away. The quest is well underway. Lee, 45, joined the renowned Stanford Cancer Institute in October 2019 with a well-defined vision: Helping an elite academic institution become even better with a program for a previously underserved population. “I had a great career in Los Angeles. I’m proud of that pro...
Identifying rare subsets of thoracic tumors with gene fusions has redefined therapeutic paradigms. Gene rearrangements involving neurotrophic tropomyosin receptor kinase, (NTRK)1, NTRK2, NTRK3, c-ROS oncogene 1 (ROS1) and the anaplastic lymphoma kinase gene (ALK), result in oncogenic fusion proteins that are detectable using immunohistochemistry screening with variable sensitivity and specificity [1 –3].
Authors: Kowalik A, Wincewicz A, Zięba S, Baran W, Kopczyński J, Koda M, Sulkowski S, Goźdź S Abstract Molecular next gene sequencing was used to evaluate mutations in 409 common mutated cancer-related genes in malignant mesothelioma of tunica vaginalis testis (MMTVT) of 81-year-old man. Multifocal papillary-solid areas contained necrosis among highly cellular fields with multiple mitoses. It was positive for WT1, CKAE1/AE3, calretinin, CK7 with negativity for CK5, PSA, TTF-1. Following mutations were revealed in PARP1 (NM_001618: c.2285TG, p.I49M) and two sorts of mutations in structure of KMT2C gene (NM_17060...
ConclusionsOur observations suggest that a molecular ‐guided treatment approach is feasible for the management of advanced malignant mesothelioma. Our analysis revealed gender specific differences in PDGFRα expression that should be further evaluated in clinical trials.
This article is protected by copyright. All rights reserved. PMID: 32437065 [PubMed - as supplied by publisher]